nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—Fenethylline—Dimenhydrinate—atopic dermatitis	0.662	0.92	CrCrCtD
Methamphetamine—SLC22A5—Diphenhydramine—atopic dermatitis	0.102	0.641	CbGbCtD
Methamphetamine—Benzphetamine—Diphenhydramine—atopic dermatitis	0.0576	0.0801	CrCrCtD
Methamphetamine—CYP2D6—Loratadine—atopic dermatitis	0.0245	0.153	CbGbCtD
Methamphetamine—CYP2D6—Diphenhydramine—atopic dermatitis	0.0245	0.153	CbGbCtD
Methamphetamine—CYP2D6—Dexamethasone—atopic dermatitis	0.00846	0.053	CbGbCtD
Methamphetamine—SLC22A5—Temsirolimus—Tacrolimus—atopic dermatitis	0.00272	0.5	CbGdCrCtD
Methamphetamine—SLC22A5—Temsirolimus—Pimecrolimus—atopic dermatitis	0.00272	0.5	CbGdCrCtD
Methamphetamine—Euphoric mood—Dimenhydrinate—atopic dermatitis	0.00266	0.034	CcSEcCtD
Methamphetamine—Euphoric mood—Diphenhydramine—atopic dermatitis	0.00266	0.034	CcSEcCtD
Methamphetamine—Pseudoephedrine—IL2—atopic dermatitis	0.00167	0.748	CrCbGaD
Methamphetamine—Tremor—Dimenhydrinate—atopic dermatitis	0.00127	0.0162	CcSEcCtD
Methamphetamine—Tremor—Diphenhydramine—atopic dermatitis	0.00127	0.0162	CcSEcCtD
Methamphetamine—Agitation—Diphenhydramine—atopic dermatitis	0.00124	0.0159	CcSEcCtD
Methamphetamine—Agitation—Dimenhydrinate—atopic dermatitis	0.00124	0.0159	CcSEcCtD
Methamphetamine—Palpitations—Dimenhydrinate—atopic dermatitis	0.0012	0.0153	CcSEcCtD
Methamphetamine—Palpitations—Diphenhydramine—atopic dermatitis	0.0012	0.0153	CcSEcCtD
Methamphetamine—Psychotic disorder—Tacrolimus—atopic dermatitis	0.00116	0.0148	CcSEcCtD
Methamphetamine—Tachycardia—Diphenhydramine—atopic dermatitis	0.00108	0.0138	CcSEcCtD
Methamphetamine—Tachycardia—Dimenhydrinate—atopic dermatitis	0.00108	0.0138	CcSEcCtD
Methamphetamine—Insomnia—Dimenhydrinate—atopic dermatitis	0.001	0.0128	CcSEcCtD
Methamphetamine—Insomnia—Diphenhydramine—atopic dermatitis	0.001	0.0128	CcSEcCtD
Methamphetamine—Dyspepsia—Dimenhydrinate—atopic dermatitis	0.000973	0.0124	CcSEcCtD
Methamphetamine—Dyspepsia—Diphenhydramine—atopic dermatitis	0.000973	0.0124	CcSEcCtD
Methamphetamine—Agitation—Loratadine—atopic dermatitis	0.000959	0.0122	CcSEcCtD
Methamphetamine—Headache—Desonide—atopic dermatitis	0.000948	0.0121	CcSEcCtD
Methamphetamine—Constipation—Dimenhydrinate—atopic dermatitis	0.000945	0.0121	CcSEcCtD
Methamphetamine—Constipation—Diphenhydramine—atopic dermatitis	0.000945	0.0121	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Pimecrolimus—atopic dermatitis	0.000923	0.0118	CcSEcCtD
Methamphetamine—Palpitations—Loratadine—atopic dermatitis	0.000922	0.0118	CcSEcCtD
Methamphetamine—Constipation—Pimecrolimus—atopic dermatitis	0.000914	0.0117	CcSEcCtD
Methamphetamine—Hypersensitivity—Fluocinonide—atopic dermatitis	0.000903	0.0115	CcSEcCtD
Methamphetamine—Euphoric mood—Prednisolone—atopic dermatitis	0.000894	0.0114	CcSEcCtD
Methamphetamine—Urticaria—Dimenhydrinate—atopic dermatitis	0.000878	0.0112	CcSEcCtD
Methamphetamine—Urticaria—Diphenhydramine—atopic dermatitis	0.000878	0.0112	CcSEcCtD
Methamphetamine—Euphoric mood—Hydrocortisone—atopic dermatitis	0.000874	0.0112	CcSEcCtD
Methamphetamine—Urticaria—Pimecrolimus—atopic dermatitis	0.000849	0.0108	CcSEcCtD
Methamphetamine—Tachycardia—Loratadine—atopic dermatitis	0.000831	0.0106	CcSEcCtD
Methamphetamine—Euphoric mood—Triamcinolone—atopic dermatitis	0.000823	0.0105	CcSEcCtD
Methamphetamine—Euphoric mood—Methylprednisolone—atopic dermatitis	0.000821	0.0105	CcSEcCtD
Methamphetamine—Dizziness—Fluocinonide—atopic dermatitis	0.000811	0.0103	CcSEcCtD
Methamphetamine—Hypersensitivity—Pimecrolimus—atopic dermatitis	0.000787	0.0101	CcSEcCtD
Methamphetamine—Insomnia—Loratadine—atopic dermatitis	0.00077	0.00983	CcSEcCtD
Methamphetamine—Headache—Fluocinonide—atopic dermatitis	0.000768	0.0098	CcSEcCtD
Methamphetamine—Diarrhoea—Diphenhydramine—atopic dermatitis	0.000756	0.00966	CcSEcCtD
Methamphetamine—Diarrhoea—Dimenhydrinate—atopic dermatitis	0.000756	0.00966	CcSEcCtD
Methamphetamine—Dyspepsia—Loratadine—atopic dermatitis	0.000749	0.00957	CcSEcCtD
Methamphetamine—Euphoric mood—Betamethasone—atopic dermatitis	0.000746	0.00953	CcSEcCtD
Methamphetamine—Euphoric mood—Dexamethasone—atopic dermatitis	0.000746	0.00953	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Loratadine—atopic dermatitis	0.000735	0.00938	CcSEcCtD
Methamphetamine—Diarrhoea—Pimecrolimus—atopic dermatitis	0.000731	0.00934	CcSEcCtD
Methamphetamine—Dizziness—Dimenhydrinate—atopic dermatitis	0.000731	0.00933	CcSEcCtD
Methamphetamine—Dizziness—Diphenhydramine—atopic dermatitis	0.000731	0.00933	CcSEcCtD
Methamphetamine—Constipation—Loratadine—atopic dermatitis	0.000728	0.00929	CcSEcCtD
Methamphetamine—Psychotic disorder—Hydrocortisone—atopic dermatitis	0.000721	0.0092	CcSEcCtD
Methamphetamine—Headache—Dimenhydrinate—atopic dermatitis	0.000692	0.00884	CcSEcCtD
Methamphetamine—Headache—Diphenhydramine—atopic dermatitis	0.000692	0.00884	CcSEcCtD
Methamphetamine—Psychotic disorder—Methylprednisolone—atopic dermatitis	0.000677	0.00865	CcSEcCtD
Methamphetamine—Headache—Pimecrolimus—atopic dermatitis	0.00067	0.00855	CcSEcCtD
Methamphetamine—Tremor—Tacrolimus—atopic dermatitis	0.000668	0.00852	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Fluocinolone Acetonide—atopic dermatitis	0.000661	0.00843	CcSEcCtD
Methamphetamine—Agitation—Tacrolimus—atopic dermatitis	0.000655	0.00836	CcSEcCtD
Methamphetamine—Euphoric mood—Prednisone—atopic dermatitis	0.00065	0.0083	CcSEcCtD
Methamphetamine—Dyspepsia—Mometasone—atopic dermatitis	0.000643	0.00821	CcSEcCtD
Methamphetamine—Palpitations—Tacrolimus—atopic dermatitis	0.00063	0.00804	CcSEcCtD
Methamphetamine—Psychotic disorder—Betamethasone—atopic dermatitis	0.000616	0.00786	CcSEcCtD
Methamphetamine—Psychotic disorder—Dexamethasone—atopic dermatitis	0.000616	0.00786	CcSEcCtD
Methamphetamine—Diarrhoea—Loratadine—atopic dermatitis	0.000582	0.00744	CcSEcCtD
Methamphetamine—Tachycardia—Tacrolimus—atopic dermatitis	0.000568	0.00724	CcSEcCtD
Methamphetamine—Hypersensitivity—Fluocinolone Acetonide—atopic dermatitis	0.000564	0.0072	CcSEcCtD
Methamphetamine—Dizziness—Loratadine—atopic dermatitis	0.000563	0.00719	CcSEcCtD
Methamphetamine—Pseudoephedrine—TNF—atopic dermatitis	0.000562	0.252	CrCbGaD
Methamphetamine—Psychotic disorder—Prednisone—atopic dermatitis	0.000536	0.00685	CcSEcCtD
Methamphetamine—Headache—Loratadine—atopic dermatitis	0.000533	0.00681	CcSEcCtD
Methamphetamine—Insomnia—Tacrolimus—atopic dermatitis	0.000526	0.00671	CcSEcCtD
Methamphetamine—Diarrhoea—Fluocinolone Acetonide—atopic dermatitis	0.000524	0.00668	CcSEcCtD
Methamphetamine—Dyspepsia—Tacrolimus—atopic dermatitis	0.000512	0.00653	CcSEcCtD
Methamphetamine—Dizziness—Fluocinolone Acetonide—atopic dermatitis	0.000506	0.00646	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Tacrolimus—atopic dermatitis	0.000502	0.00641	CcSEcCtD
Methamphetamine—Diarrhoea—Mometasone—atopic dermatitis	0.0005	0.00638	CcSEcCtD
Methamphetamine—Constipation—Tacrolimus—atopic dermatitis	0.000497	0.00635	CcSEcCtD
Methamphetamine—Headache—Fluocinolone Acetonide—atopic dermatitis	0.000479	0.00612	CcSEcCtD
Methamphetamine—Urticaria—Tacrolimus—atopic dermatitis	0.000462	0.0059	CcSEcCtD
Methamphetamine—Headache—Mometasone—atopic dermatitis	0.000458	0.00584	CcSEcCtD
Methamphetamine—Erectile dysfunction—Prednisone—atopic dermatitis	0.000437	0.00558	CcSEcCtD
Methamphetamine—Hypersensitivity—Tacrolimus—atopic dermatitis	0.000428	0.00547	CcSEcCtD
Methamphetamine—Diarrhoea—Tacrolimus—atopic dermatitis	0.000398	0.00508	CcSEcCtD
Methamphetamine—Dizziness—Tacrolimus—atopic dermatitis	0.000385	0.00491	CcSEcCtD
Methamphetamine—Headache—Tacrolimus—atopic dermatitis	0.000364	0.00465	CcSEcCtD
Methamphetamine—Tachycardia—Prednisolone—atopic dermatitis	0.000362	0.00463	CcSEcCtD
Methamphetamine—Tachycardia—Hydrocortisone—atopic dermatitis	0.000354	0.00452	CcSEcCtD
Methamphetamine—Insomnia—Prednisolone—atopic dermatitis	0.000336	0.00429	CcSEcCtD
Methamphetamine—Tachycardia—Triamcinolone—atopic dermatitis	0.000333	0.00426	CcSEcCtD
Methamphetamine—Tachycardia—Methylprednisolone—atopic dermatitis	0.000333	0.00425	CcSEcCtD
Methamphetamine—Insomnia—Hydrocortisone—atopic dermatitis	0.000328	0.00419	CcSEcCtD
Methamphetamine—Dyspepsia—Hydrocortisone—atopic dermatitis	0.000319	0.00408	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.000313	0.004	CcSEcCtD
Methamphetamine—Insomnia—Triamcinolone—atopic dermatitis	0.000309	0.00394	CcSEcCtD
Methamphetamine—Insomnia—Methylprednisolone—atopic dermatitis	0.000308	0.00393	CcSEcCtD
Methamphetamine—Agitation—Prednisone—atopic dermatitis	0.000304	0.00388	CcSEcCtD
Methamphetamine—Tachycardia—Dexamethasone—atopic dermatitis	0.000302	0.00386	CcSEcCtD
Methamphetamine—Tachycardia—Betamethasone—atopic dermatitis	0.000302	0.00386	CcSEcCtD
Methamphetamine—Dyspepsia—Triamcinolone—atopic dermatitis	0.000301	0.00384	CcSEcCtD
Methamphetamine—Dyspepsia—Methylprednisolone—atopic dermatitis	0.0003	0.00383	CcSEcCtD
Methamphetamine—Urticaria—Prednisolone—atopic dermatitis	0.000295	0.00377	CcSEcCtD
Methamphetamine—Urticaria—Hydrocortisone—atopic dermatitis	0.000288	0.00368	CcSEcCtD
Methamphetamine—Insomnia—Betamethasone—atopic dermatitis	0.00028	0.00358	CcSEcCtD
Methamphetamine—Insomnia—Dexamethasone—atopic dermatitis	0.00028	0.00358	CcSEcCtD
Methamphetamine—Hypersensitivity—Prednisolone—atopic dermatitis	0.000274	0.00349	CcSEcCtD
Methamphetamine—Dyspepsia—Dexamethasone—atopic dermatitis	0.000273	0.00348	CcSEcCtD
Methamphetamine—Dyspepsia—Betamethasone—atopic dermatitis	0.000273	0.00348	CcSEcCtD
Methamphetamine—Urticaria—Triamcinolone—atopic dermatitis	0.000271	0.00346	CcSEcCtD
Methamphetamine—Urticaria—Methylprednisolone—atopic dermatitis	0.000271	0.00346	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	0.000268	0.00342	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Betamethasone—atopic dermatitis	0.000268	0.00342	CcSEcCtD
Methamphetamine—Hypersensitivity—Hydrocortisone—atopic dermatitis	0.000267	0.00341	CcSEcCtD
Methamphetamine—Tachycardia—Prednisone—atopic dermatitis	0.000263	0.00336	CcSEcCtD
Methamphetamine—Hypersensitivity—Triamcinolone—atopic dermatitis	0.000252	0.00321	CcSEcCtD
Methamphetamine—Hypersensitivity—Methylprednisolone—atopic dermatitis	0.000251	0.00321	CcSEcCtD
Methamphetamine—Diarrhoea—Hydrocortisone—atopic dermatitis	0.000248	0.00317	CcSEcCtD
Methamphetamine—Urticaria—Dexamethasone—atopic dermatitis	0.000246	0.00314	CcSEcCtD
Methamphetamine—Urticaria—Betamethasone—atopic dermatitis	0.000246	0.00314	CcSEcCtD
Methamphetamine—Dizziness—Prednisolone—atopic dermatitis	0.000246	0.00314	CcSEcCtD
Methamphetamine—Insomnia—Prednisone—atopic dermatitis	0.000244	0.00312	CcSEcCtD
Methamphetamine—Dizziness—Hydrocortisone—atopic dermatitis	0.00024	0.00306	CcSEcCtD
Methamphetamine—Dyspepsia—Prednisone—atopic dermatitis	0.000238	0.00303	CcSEcCtD
Methamphetamine—Diarrhoea—Methylprednisolone—atopic dermatitis	0.000233	0.00298	CcSEcCtD
Methamphetamine—Headache—Prednisolone—atopic dermatitis	0.000233	0.00297	CcSEcCtD
Methamphetamine—Constipation—Prednisone—atopic dermatitis	0.000231	0.00295	CcSEcCtD
Methamphetamine—Headache—Hydrocortisone—atopic dermatitis	0.000227	0.0029	CcSEcCtD
Methamphetamine—Dizziness—Triamcinolone—atopic dermatitis	0.000226	0.00288	CcSEcCtD
Methamphetamine—Dizziness—Methylprednisolone—atopic dermatitis	0.000225	0.00288	CcSEcCtD
Methamphetamine—Urticaria—Prednisone—atopic dermatitis	0.000214	0.00274	CcSEcCtD
Methamphetamine—Headache—Triamcinolone—atopic dermatitis	0.000214	0.00273	CcSEcCtD
Methamphetamine—Headache—Methylprednisolone—atopic dermatitis	0.000213	0.00273	CcSEcCtD
Methamphetamine—Diarrhoea—Dexamethasone—atopic dermatitis	0.000212	0.00271	CcSEcCtD
Methamphetamine—Diarrhoea—Betamethasone—atopic dermatitis	0.000212	0.00271	CcSEcCtD
Methamphetamine—Dizziness—Betamethasone—atopic dermatitis	0.000205	0.00262	CcSEcCtD
Methamphetamine—Dizziness—Dexamethasone—atopic dermatitis	0.000205	0.00262	CcSEcCtD
Methamphetamine—Hypersensitivity—Prednisone—atopic dermatitis	0.000199	0.00254	CcSEcCtD
Methamphetamine—Headache—Betamethasone—atopic dermatitis	0.000194	0.00248	CcSEcCtD
Methamphetamine—Headache—Dexamethasone—atopic dermatitis	0.000194	0.00248	CcSEcCtD
Methamphetamine—Diarrhoea—Prednisone—atopic dermatitis	0.000185	0.00236	CcSEcCtD
Methamphetamine—Dizziness—Prednisone—atopic dermatitis	0.000178	0.00228	CcSEcCtD
Methamphetamine—Headache—Prednisone—atopic dermatitis	0.000169	0.00216	CcSEcCtD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CCL5—atopic dermatitis	6.15e-05	0.00177	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CCR3—atopic dermatitis	6.12e-05	0.00176	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CCL11—atopic dermatitis	6.1e-05	0.00175	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	6.08e-05	0.00175	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—KIF3A—atopic dermatitis	6.03e-05	0.00173	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—SELE—atopic dermatitis	5.98e-05	0.00172	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL5—atopic dermatitis	5.98e-05	0.00172	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCL22—atopic dermatitis	5.98e-05	0.00172	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—CCR5—atopic dermatitis	5.93e-05	0.0017	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GLB1—atopic dermatitis	5.89e-05	0.00169	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CCL27—atopic dermatitis	5.87e-05	0.00169	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—NPS—atopic dermatitis	5.84e-05	0.00168	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—TAC1—atopic dermatitis	5.84e-05	0.00168	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—NPS—atopic dermatitis	5.82e-05	0.00167	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TAC1—atopic dermatitis	5.82e-05	0.00167	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	5.8e-05	0.00167	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CXCL10—atopic dermatitis	5.8e-05	0.00167	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CXCR3—atopic dermatitis	5.73e-05	0.00164	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—atopic dermatitis	5.71e-05	0.00164	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCL27—atopic dermatitis	5.7e-05	0.00164	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	5.68e-05	0.00163	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—CXCL8—atopic dermatitis	5.65e-05	0.00162	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—ADSL—atopic dermatitis	5.64e-05	0.00162	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CCR5—atopic dermatitis	5.54e-05	0.00159	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	5.5e-05	0.00158	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—NPS—atopic dermatitis	5.45e-05	0.00157	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—TAC1—atopic dermatitis	5.45e-05	0.00157	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—IL1B—atopic dermatitis	5.42e-05	0.00156	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CXCR3—atopic dermatitis	5.35e-05	0.00154	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCL27—atopic dermatitis	5.33e-05	0.00153	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	5.23e-05	0.0015	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	5.14e-05	0.00148	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCL17—atopic dermatitis	5.12e-05	0.00147	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CXCL10—atopic dermatitis	5.1e-05	0.00146	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CCL5—atopic dermatitis	4.99e-05	0.00143	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CCR3—atopic dermatitis	4.97e-05	0.00143	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—MAPK8—atopic dermatitis	4.95e-05	0.00142	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	4.89e-05	0.0014	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SELE—atopic dermatitis	4.86e-05	0.0014	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL22—atopic dermatitis	4.86e-05	0.00139	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—IL5—atopic dermatitis	4.85e-05	0.00139	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—atopic dermatitis	4.8e-05	0.00138	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCL17—atopic dermatitis	4.78e-05	0.00137	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CCL27—atopic dermatitis	4.77e-05	0.00137	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—PPARA—atopic dermatitis	4.72e-05	0.00135	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	4.71e-05	0.00135	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CXCL10—atopic dermatitis	4.63e-05	0.00133	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	4.61e-05	0.00132	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—IL5—atopic dermatitis	4.53e-05	0.0013	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CCR5—atopic dermatitis	4.5e-05	0.00129	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—CXCL8—atopic dermatitis	4.46e-05	0.00128	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—NPS—atopic dermatitis	4.43e-05	0.00127	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—TAC1—atopic dermatitis	4.43e-05	0.00127	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	4.4e-05	0.00126	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CCL5—atopic dermatitis	4.39e-05	0.00126	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GLB1—atopic dermatitis	4.37e-05	0.00125	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CXCR3—atopic dermatitis	4.34e-05	0.00125	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL27—atopic dermatitis	4.33e-05	0.00124	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CXCL10—atopic dermatitis	4.32e-05	0.00124	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—IL2—atopic dermatitis	4.26e-05	0.00122	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ADSL—atopic dermatitis	4.19e-05	0.0012	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	4.17e-05	0.0012	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCL11—atopic dermatitis	4.12e-05	0.00118	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—PPARA—atopic dermatitis	4.08e-05	0.00117	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FCER2—atopic dermatitis	4.07e-05	0.00117	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—PPARA—atopic dermatitis	4.07e-05	0.00117	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NGF—atopic dermatitis	4.07e-05	0.00117	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CXCL8—atopic dermatitis	4.05e-05	0.00116	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CCL5—atopic dermatitis	3.98e-05	0.00114	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	3.97e-05	0.00114	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CCR5—atopic dermatitis	3.95e-05	0.00114	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—TNF—atopic dermatitis	3.93e-05	0.00113	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL17—atopic dermatitis	3.88e-05	0.00111	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—atopic dermatitis	3.87e-05	0.00111	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—IL2—atopic dermatitis	3.87e-05	0.00111	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCL11—atopic dermatitis	3.85e-05	0.00111	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FCER2—atopic dermatitis	3.8e-05	0.00109	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL22—atopic dermatitis	3.78e-05	0.00109	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CCL5—atopic dermatitis	3.72e-05	0.00107	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CCR3—atopic dermatitis	3.7e-05	0.00106	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IL5—atopic dermatitis	3.68e-05	0.00106	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—IL2—atopic dermatitis	3.6e-05	0.00103	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GLB1—atopic dermatitis	3.59e-05	0.00103	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CCR5—atopic dermatitis	3.59e-05	0.00103	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—CXCL8—atopic dermatitis	3.58e-05	0.00103	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	3.58e-05	0.00103	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL22—atopic dermatitis	3.53e-05	0.00101	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CXCL10—atopic dermatitis	3.51e-05	0.00101	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CCR3—atopic dermatitis	3.46e-05	0.000993	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ADSL—atopic dermatitis	3.44e-05	0.000989	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL27—atopic dermatitis	3.37e-05	0.000968	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCR3—atopic dermatitis	3.36e-05	0.000966	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—IL2—atopic dermatitis	3.36e-05	0.000965	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CCR5—atopic dermatitis	3.35e-05	0.000963	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NFKBIA—atopic dermatitis	3.35e-05	0.000963	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CXCL8—atopic dermatitis	3.35e-05	0.000962	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—TAC1—atopic dermatitis	3.3e-05	0.000948	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—NPS—atopic dermatitis	3.3e-05	0.000948	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCR3—atopic dermatitis	3.24e-05	0.000929	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—PPARA—atopic dermatitis	3.17e-05	0.000912	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—IL6—atopic dermatitis	3.17e-05	0.000911	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—IL6—atopic dermatitis	3.16e-05	0.000908	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL27—atopic dermatitis	3.15e-05	0.000904	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCR3—atopic dermatitis	3.14e-05	0.000902	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL11—atopic dermatitis	3.13e-05	0.000899	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FCER2—atopic dermatitis	3.09e-05	0.000886	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—TAC1—atopic dermatitis	3.08e-05	0.000885	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—NPS—atopic dermatitis	3.08e-05	0.000885	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—IL5—atopic dermatitis	3.07e-05	0.000881	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CCL5—atopic dermatitis	3.02e-05	0.000868	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCR3—atopic dermatitis	3.02e-05	0.000868	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL17—atopic dermatitis	3.02e-05	0.000868	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—NPS—atopic dermatitis	3e-05	0.000861	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—TAC1—atopic dermatitis	3e-05	0.000861	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCR3—atopic dermatitis	2.94e-05	0.000844	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GLB1—atopic dermatitis	2.92e-05	0.000838	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL22—atopic dermatitis	2.87e-05	0.000824	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—IL5—atopic dermatitis	2.87e-05	0.000823	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	2.85e-05	0.000818	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL17—atopic dermatitis	2.82e-05	0.000811	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—PPARA—atopic dermatitis	2.81e-05	0.000807	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CCR3—atopic dermatitis	2.81e-05	0.000807	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—NPS—atopic dermatitis	2.8e-05	0.000804	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—TAC1—atopic dermatitis	2.8e-05	0.000804	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ADSL—atopic dermatitis	2.8e-05	0.000803	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL5—atopic dermatitis	2.79e-05	0.0008	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCR3—atopic dermatitis	2.75e-05	0.000788	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—IL2—atopic dermatitis	2.73e-05	0.000784	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CCR5—atopic dermatitis	2.72e-05	0.000782	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CXCL8—atopic dermatitis	2.72e-05	0.000781	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KIF3A—atopic dermatitis	2.69e-05	0.000774	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	2.66e-05	0.000765	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCL10—atopic dermatitis	2.62e-05	0.000751	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL5—atopic dermatitis	2.6e-05	0.000747	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL27—atopic dermatitis	2.56e-05	0.000734	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCR3—atopic dermatitis	2.55e-05	0.000733	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KIF3A—atopic dermatitis	2.52e-05	0.000723	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—TAC1—atopic dermatitis	2.5e-05	0.000719	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—NPS—atopic dermatitis	2.5e-05	0.000719	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCR3—atopic dermatitis	2.46e-05	0.000705	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCL10—atopic dermatitis	2.44e-05	0.000702	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CMA1—atopic dermatitis	2.44e-05	0.0007	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL11—atopic dermatitis	2.44e-05	0.0007	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CXCL8—atopic dermatitis	2.39e-05	0.000687	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCL10—atopic dermatitis	2.38e-05	0.000682	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—IL5—atopic dermatitis	2.33e-05	0.000668	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL17—atopic dermatitis	2.29e-05	0.000659	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—STAT6—atopic dermatitis	2.29e-05	0.000658	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL2—atopic dermatitis	2.29e-05	0.000656	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL11—atopic dermatitis	2.28e-05	0.000654	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CMA1—atopic dermatitis	2.28e-05	0.000654	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—IL6—atopic dermatitis	2.27e-05	0.000653	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—NPS—atopic dermatitis	2.27e-05	0.000653	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—TAC1—atopic dermatitis	2.27e-05	0.000653	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PPARA—atopic dermatitis	2.26e-05	0.000648	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CCL5—atopic dermatitis	2.25e-05	0.000647	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCR3—atopic dermatitis	2.23e-05	0.00064	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCL10—atopic dermatitis	2.22e-05	0.000637	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CXCL8—atopic dermatitis	2.17e-05	0.000623	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	2.16e-05	0.000621	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—STAT6—atopic dermatitis	2.14e-05	0.000614	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL5—atopic dermatitis	2.11e-05	0.000607	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CCL5—atopic dermatitis	2.1e-05	0.000604	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—MAPK8—atopic dermatitis	2.1e-05	0.000604	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCL5—atopic dermatitis	2.04e-05	0.000587	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KIF3A—atopic dermatitis	2.04e-05	0.000587	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CCR5—atopic dermatitis	2.03e-05	0.000583	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CXCL8—atopic dermatitis	2.03e-05	0.000582	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCR3—atopic dermatitis	1.99e-05	0.00057	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL10—atopic dermatitis	1.98e-05	0.00057	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PPARA—atopic dermatitis	1.91e-05	0.000549	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCL5—atopic dermatitis	1.91e-05	0.000549	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GLB1—atopic dermatitis	1.9e-05	0.000546	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CCR5—atopic dermatitis	1.89e-05	0.000544	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCR3—atopic dermatitis	1.86e-05	0.000533	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—IL2—atopic dermatitis	1.85e-05	0.000533	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CMA1—atopic dermatitis	1.85e-05	0.000531	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL11—atopic dermatitis	1.85e-05	0.000531	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCR5—atopic dermatitis	1.84e-05	0.000529	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ADSL—atopic dermatitis	1.82e-05	0.000523	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL10—atopic dermatitis	1.8e-05	0.000518	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NPS—atopic dermatitis	1.77e-05	0.000508	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TAC1—atopic dermatitis	1.77e-05	0.000508	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STAT6—atopic dermatitis	1.74e-05	0.000499	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCR3—atopic dermatitis	1.74e-05	0.000499	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—IL2—atopic dermatitis	1.73e-05	0.000498	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCR5—atopic dermatitis	1.72e-05	0.000494	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CCL5—atopic dermatitis	1.71e-05	0.000491	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NPS—atopic dermatitis	1.65e-05	0.000475	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TAC1—atopic dermatitis	1.65e-05	0.000475	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CXCL8—atopic dermatitis	1.65e-05	0.000473	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL5—atopic dermatitis	1.65e-05	0.000473	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCR3—atopic dermatitis	1.62e-05	0.000466	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL5—atopic dermatitis	1.55e-05	0.000446	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CCR5—atopic dermatitis	1.54e-05	0.000442	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL5—atopic dermatitis	1.54e-05	0.000441	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCR3—atopic dermatitis	1.51e-05	0.000433	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PPARA—atopic dermatitis	1.42e-05	0.000407	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IL2—atopic dermatitis	1.41e-05	0.000404	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL10—atopic dermatitis	1.4e-05	0.000403	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCR5—atopic dermatitis	1.4e-05	0.000401	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL6—atopic dermatitis	1.34e-05	0.000386	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TAC1—atopic dermatitis	1.34e-05	0.000386	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NPS—atopic dermatitis	1.34e-05	0.000386	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCR3—atopic dermatitis	1.32e-05	0.000378	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL10—atopic dermatitis	1.31e-05	0.000376	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL5—atopic dermatitis	1.25e-05	0.000359	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCL8—atopic dermatitis	1.23e-05	0.000352	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL5—atopic dermatitis	1.21e-05	0.000347	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—IL2—atopic dermatitis	1.17e-05	0.000337	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PPARA—atopic dermatitis	1.17e-05	0.000335	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCL8—atopic dermatitis	1.15e-05	0.000329	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL5—atopic dermatitis	1.13e-05	0.000324	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NGF—atopic dermatitis	1.12e-05	0.000321	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCL8—atopic dermatitis	1.11e-05	0.00032	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—IL2—atopic dermatitis	1.09e-05	0.000314	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCR5—atopic dermatitis	1.09e-05	0.000313	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL10—atopic dermatitis	1.06e-05	0.000306	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL2—atopic dermatitis	1.06e-05	0.000306	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NGF—atopic dermatitis	1.04e-05	0.0003	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCL8—atopic dermatitis	1.04e-05	0.000299	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCR5—atopic dermatitis	1.02e-05	0.000292	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL2—atopic dermatitis	9.94e-06	0.000286	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PPARA—atopic dermatitis	9.47e-06	0.000272	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL8—atopic dermatitis	9.31e-06	0.000267	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NFKBIA—atopic dermatitis	9.23e-06	0.000265	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL5—atopic dermatitis	9.16e-06	0.000263	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—IL2—atopic dermatitis	8.89e-06	0.000255	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NFKBIA—atopic dermatitis	8.62e-06	0.000247	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NGF—atopic dermatitis	8.49e-06	0.000244	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL8—atopic dermatitis	8.45e-06	0.000243	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCR5—atopic dermatitis	8.26e-06	0.000237	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL2—atopic dermatitis	8.08e-06	0.000232	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NFKBIA—atopic dermatitis	7e-06	0.000201	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL8—atopic dermatitis	6.58e-06	0.000189	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL2—atopic dermatitis	6.29e-06	0.000181	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—atopic dermatitis	6.26e-06	0.00018	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPARA—atopic dermatitis	6.17e-06	0.000177	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL8—atopic dermatitis	6.15e-06	0.000176	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL2—atopic dermatitis	5.87e-06	0.000169	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—atopic dermatitis	5.84e-06	0.000168	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAPK8—atopic dermatitis	5.79e-06	0.000166	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAPK8—atopic dermatitis	5.41e-06	0.000155	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL8—atopic dermatitis	4.99e-06	0.000143	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL2—atopic dermatitis	4.77e-06	0.000137	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—atopic dermatitis	4.75e-06	0.000136	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAPK8—atopic dermatitis	4.39e-06	0.000126	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—atopic dermatitis	3.7e-06	0.000106	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—atopic dermatitis	3.45e-06	9.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—atopic dermatitis	2.8e-06	8.05e-05	CbGpPWpGaD
